{"classes":[{"categories":[{"measurements":[{"comment":"Duration of response was not reached for Cohorts A and B due to fewer number of participants with events.","groupId":"OG000","lowerLimit":"36","upperLimit":"2172","value":"NA"},{"comment":"Duration of response was not reached for Cohorts A and B due to fewer number of participants with events.","groupId":"OG001","lowerLimit":"33","upperLimit":"2171","value":"NA"},{"groupId":"OG002","lowerLimit":"35","upperLimit":"2079","value":"360.0"},{"groupId":"OG003","lowerLimit":"42","upperLimit":"1334","value":"732.0"},{"groupId":"OG004","lowerLimit":"54","upperLimit":"1811","value":"196.0"},{"groupId":"OG005","lowerLimit":"54","upperLimit":"1038","value":"108.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"192"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"37"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"15"}],"units":"Participants"}],"title":"Hematologic Response"},{"categories":[{"measurements":[{"comment":"Duration of response was not reached for Cohorts A and B due to fewer number of participants with events.","groupId":"OG000","lowerLimit":"1","upperLimit":"1963","value":"NA"},{"comment":"Duration of response was not reached for Cohorts A and B due to fewer number of participants with events.","groupId":"OG001","lowerLimit":"1","upperLimit":"1903","value":"NA"},{"comment":"Duration of response was not reached due to fewer number of participants with events.","groupId":"OG002","lowerLimit":"1","upperLimit":"1779","value":"NA"},{"groupId":"OG003","lowerLimit":"28","upperLimit":"1569","value":"728.0"},{"comment":"Duration of response was not reached due to fewer number of participants with events.","groupId":"OG004","lowerLimit":"1","upperLimit":"1770","value":"NA"},{"groupId":"OG005","lowerLimit":"1","upperLimit":"673","value":"63.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"16"}],"units":"Participants"}],"title":"Cytogenetic Response"},{"categories":[{"measurements":[{"comment":"Duration of response was not reached for Cohorts A and B due to fewer number of participants with events.","groupId":"OG000","lowerLimit":"78","upperLimit":"1891","value":"NA"},{"comment":"Duration of response was not reached for Cohorts A and B due to fewer number of participants with events.","groupId":"OG001","lowerLimit":"1","upperLimit":"1899","value":"NA"},{"groupId":"OG002","lowerLimit":"1","upperLimit":"1666","value":"560.0"},{"groupId":"OG003","lowerLimit":"1","upperLimit":"783","value":"222.0"},{"comment":"Duration of response was not reached due to fewer number of participants with events.","groupId":"OG004","lowerLimit":"1","upperLimit":"1742","value":"NA"},{"groupId":"OG005","lowerLimit":"1","upperLimit":"98","value":"98.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"2"}],"units":"Participants"}],"title":"Molecular Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"203"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"65"},{"groupId":"OG003","value":"18"},{"groupId":"OG004","value":"48"},{"groupId":"OG005","value":"46"}],"units":"Participants"}],"description":"Duration of Response is defined as the interval between the first assessment at which the criteria for response are met until the criteria for progression are met, censored at the last date at which the criteria for response are met. Duration of response was estimated by the Kaplan-Meier method as the probability of remaining in response.","dispersionType":"Full Range","groups":[{"description":"CP-CML participants R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG000","title":"Cohort A: CP-CML R-I"},{"description":"CP-CML participants who had T315I mutation of breakpoint cluster region-Abelson complex (BCR-ABL) were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG001","title":"Cohort B: CP-CML With T315I Mutation"},{"description":"AP-CML R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG002","title":"Cohort C: AP-CML R-I"},{"description":"AP-CML participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG003","title":"Cohort D: AP-CML With T315I Mutation"},{"description":"BP-CML or Ph+ ALL R-I to dasatinib or nilotinib or Ph+ ALL R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG004","title":"Cohort E: BP-CML/Ph+ ALL R-I"},{"description":"BP-CML or Ph+ ALL participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG005","title":"Cohort F: BP-CML or Ph+ ALL With T315I Mutation"}],"paramType":"MEDIAN","populationDescription":"Treated population included all participants assigned to Cohorts A to F who received at least 1 dose of ponatinib. Number analyzed is number of participants with data available for analysis at given time-point","reportingStatus":"POSTED","timeFrame":"Up to approximately 48 months after first dose","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"days"}